- Home
- PCRX vs PML Comparison
PCRX vs PML Comparison
Compare PCRX & PML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCRX | PML |
|---|---|---|
| Founded | 2006 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 502.0M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | PCRX | PML |
|---|---|---|
| Price | $26.26 | $7.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $32.86 | N/A |
| AVG Volume (30 Days) | ★ 761.2K | 188.0K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.65% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $716,791,000.00 | N/A |
| Revenue This Year | $6.24 | N/A |
| Revenue Next Year | $9.53 | N/A |
| P/E Ratio | $55.55 | ★ N/A |
| Revenue Growth | ★ 3.14 | N/A |
| 52 Week Low | $18.17 | $6.92 |
| 52 Week High | $27.64 | $9.46 |
Technical Indicators
Market Signals| Indicator | PCRX | PML |
|---|---|---|
| Relative Strength Index (RSI) | 67.86 | 33.33 |
| Support Level | $25.17 | $7.53 |
| Resistance Level | $24.81 | $7.68 |
| Average True Range (ATR) | 0.96 | 0.05 |
| MACD | 0.26 | -0.01 |
| Stochastic Oscillator | 76.49 | 23.88 |
Price Performance
Historical ComparisonAbout PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About PML Pimco Municipal Income Fund II of Beneficial Interest
PIMCO Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as education, healthcare, and others.